Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old

Inclusion Criteria: * Male/Female children aged 5-11 years * Written informed consent obtained by parents/legal representative (according to local regulation) and by the minor (age and local regulation permitting). * children with stable asthma on regular treatment with ICS or using short-acting inhaled beta2-agonists as reliever to control asthma symptoms * Forced expiratory volume in one second (FEV1) \> 70% of predicted values (% pred) after withholding beta2-agonist treatment for a minimum of 4 h prior to each dose period. 6\. A cooperative attitude and ability to be trained about the proper use of pMDI with a spacer device and compliant to study procedures. Exclusion Criteria: * Past or present diagnoses of cardiovascular, renal or liver disease * Known hypersensitivity to the active treatments * Exacerbation of asthma symptoms within the previous 4 weeks * Inability to perform the required breathing technique and blood sampling * Hospitalization due to exacerbation of asthma within 1 month prior to inclusion * Lower respiratory tract infection within 1 month prior to inclusion * Disease (other than asthma) which might influence the outcome of the study * Obesity, i.e. \> 97% weight percentile by local standards